The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 196
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President | 1.79M | N/D | 1959 |
Mr. Michael A. Jacobsen | Chief Accounting Officer, VP of Finance & Treasurer | 518.6k | N/D | 1958 |
Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary | 503.24k | N/D | 1979 |
Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder | N/D | N/D | 1963 |
Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science | N/D | N/D | 1957 |
Mr. Peter W. Williams | Vice President of Human Resources | N/D | N/D | 1968 |
Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | N/D | N/D | 1959 |
Ms. Nadia Dac | VP & Chief Commercial Officer | N/D | N/D | 1970 |
Dr. Andreas Grauer M.D. | Chief Medical Officer | N/D | N/D | 1961 |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
La calificación ISS Governance QuickScore de Omeros Corporation a partir del 1 de marzo de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 9; Derechos del accionista: 5; Compensación: 8.